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While cannabis may be used by women during pregnancy, its effects on their 
offsprings’ developing stress response system are still largely unknown. The binding 
sites for the active chemicals in cannabis are operational at early time points in fetal 
development and are expressed in key limbic brain structures. The body’s natural 
endocannabinoid system serves as an important regulator of the stress response. 
Longitudinal studies have associated prenatal exposure with increased fearfulness and 
mood disturbances in offspring, but, despite the growing evidence of emotional 
dysfunction, there remains a critical gap in knowledge explaining how early prenatal 
exposure may lead to future affective pathology. 
The purpose of the current study was to attempt to fill in this gap by 
investigating deviations in stress-related hormone concentrations at early 
developmental time points. Infants prenatally exposed to cannabis demonstrated 
significantly higher concentrations of cortisol F (1, 176) = 11.82, p < .001; n2 = .06, and 
these results remained largely unchanged when covarying for biological and 




concentrations of dehydroepiandrosterone (DHEA) as well, F (1, 223) = 6.07, p = .02, n2 
= .02, and this finding remained significant when adjusting for biological factors but not 
maternal sociodemographic variables. Maternal anxiety, birthweight, and other 
prenatal substance exposures significantly interacted with prenatal cannabis exposure 
to produce higher concentrations of stress hormones. Lastly, higher levels of biological 
stress hormones were significantly associated with higher levels of reported anxiety but 
only within the prenatal cannabis exposed group. Cortisol and DHEA are both 
hormones that play an important role in the regulation of the stress response system. 
This study reports hormone alterations in substance-exposed offspring that may 
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The prenatal period is a unique point in development where exposure to 
elements in utero may mirror or amplify risks that are known to be associated with 
direct postnatal exposure. As the newly formed brain is developing, its vulnerability to 
external influences makes studying potential risks during this time point crucial. One 
such potential risk factor is maternal drug use during pregnancy. Although much 
prenatal research has been conducted on substances like alcohol, tobacco, and cocaine 
(Lambert & Bauer, 2012; Polanska et al., 2015), research on prenatal exposure to 
marijuana (known in the substance abuse literature as cannabis) is still in its infancy 
despite widespread use among pregnant women. Although, anecdotally, cannabis use 
in adults is viewed as relatively benign long-term, cannabis’s intimate relationship with 
the stress-response system leaves many questions unanswered concerning its influence 
on emotional functioning (Yoo et al., 2019). This concern is appropriate not just for adult 
cannabis users but extends to the fetal/embryonic brain, which is vulnerable to 
disruption by external influences during crucial early developmental periods.  
With the recent legalization of marijuana in several U.S. states and with 
increased use by women of child-bearing age, studies documenting the effects of in 
utero exposure on the developing offspring are of significant value to public health and 




development/stress response, particularly when exposure is during the prenatal 
period. In order to accomplish this, this paper first outlines how the body’s stress 
response typically functions and how the natural endocannabinoid system modulates 
this. Next, this paper explores how cannabis works in the brain and how direct cannabis 
exposure affects adult emotions and stress response. Understanding the effects of direct 
exposure in adult users offers a roadmap of what might be expected in the prenatal 
literature and an understanding of possible mechanisms. Longitudinal emotional 
outcomes are discussed as well as the typical development of the endocannabinoid and 
stress response system in fetal life, infancy, and childhood, and how cannabis exposure 
can impact function.  
Though there are many unanswered questions, this paper presents what is 
currently known about this important topic and discusses crucial gaps in the literature. 
Next, this paper discusses original research investigating possible early deviations in 
stress response in prenatally exposed infants. This research explores birth outcomes, 
relevant maternal attributes, reports of offspring emotional functioning, as well as 
hormone assays that focus on two major stress hormones collected during infancy. 
Findings are discussed within the context of the current literature, and future directions 








Function of the HPA axis & endocannabinoid system 
Knowledge of cannabis’s varying interactions with human emotions, particularly 
anxiety, was evident as early as 2350 BC, with ancient writing describing the cannabis 
plant as “for or against panic” (Russo, 2007). Drawing from ancient practices, medicinal 
cannabis made a documented appearance in the United States in the 19th century, with 
case studies published about using cannabis to treat mood disorders such as modern-
day bipolar disorder. In order to best understand how prenatal cannabis exposure may 
potentially affect the emotions and stress-response of exposed offspring, it is important 
to first understand the biological mechanisms of the stress-response system and how 
the brain’s internal cannabinoid system naturally mediates this response.  
The hypothalamic-pituitary-adrenal (HPA) axis is crucial for stress response and 
overall emotional functioning, and it is heavily influenced by the body’s natural 
cannabinoid system (Hill et al., 2009; Sullivan & Dufresne, 2006). Once a threat is 
identified in the environment, there is a typical stress response cascade within the HPA 
axis that begins with the release of corticotrophin-releasing hormone (CRH) from the 
paraventricular nucleus (PVN) of the hypothalamus (Herman et al., 2005). The release 
of CRH triggers the release of adrenocorticotropic hormone (ACTH) from the anterior 
pituitary gland. ACTH binds to ACTH receptors in the adrenal gland, releasing cortisol 
and dehydroepiandrosterone (DHEA) into the bloodstream. These end-products of the 
HPA axis can be assessed in human infants and children, and serve as important 




Cortisol is one of the most widely used markers of stress response in humans 
(Russell et al., 2011). An increase in cortisol within the body facilitates the release of 
glucose for energy within cells and generally diverts activity away from non-essential 
bodily functions during a stressful experience (Van Voorhees et al., 2014). Cortisol 
additionally provides rapid negative feedback of the stress response by inhibiting CRH 
release from the paraventricular nucleus (PVN) in the hypothalamus, thus halting HPA 
activity. Cortisol release in response to stress is, therefore, essential both for appropriate 
responses to threats and for the HPA axis to recover from a threat.  
Several other brain structures, like the amygdala, prefrontal cortex (PFC), and 
hippocampus, also influence the activity of the HPA axis via communication with the 
hypothalamus, either inhibiting the stress response cascade or contributing to its 
activation (Jankord & Herman, 2008). The PFC typically has inhibitory effects on the 
HPA axis, ultimately stopping the downstream release of glucocorticoids. Specifically, 
neurons in the prelimbic region of the medial PFC activate GABAergic neurons in the 
bed nucleus of the stria terminalis (inhibitory relays to the hypothalamus) which inhibit 
the HPA axis (Ulrich-Lai & Herman, 2009). The hippocampus has GABAergic outputs 
to the hypothalamus that similarly inhibit the start of the stress cascade. The amygdala 
similarly has GABAergic outputs, but, unlike the PFC and hippocampus, the amygdala 
increases HPA activity instead of inhibiting it. It does so indirectly by inhibiting 
inhibitory inputs to the hypothalamus (Jankord & Herman, 2008). The hypothalamus, 





One of the crucial functions of endocannabinoids is to habituate stress responses 
via the HPA axis in order to maintain or restore emotional balance (Mechoulam & 
Parker, 2013). The human body naturally produces two types of endogenous 
cannabinoids (termed “endocannabinoids”): anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) (Devane et al., 1988; Mechoulam & Parker, 2013). They are 
synthesized and released from axon terminals and are retrograde messengers that 
interact with presynaptic cannabinoid type 1 (CB1) receptors (Gulyas et al., 2004; Mato 
et al., 2003). In humans, the highest density of CB1 receptors is found in the amygdala, 
hippocampus, prefrontal cortex, nucleus accumbens, and caudate-putamen, areas that, 
as previously mentioned, influence the activity of the HPA axis (Glass et al. 1997; 
Herkenham et al., 1990). Endocannabinoids are, thus, considered neuromodulators, 
influencing the activity between neurons in different brain regions (Hill et al., 2007). 
Endocannabinoids are generally inhibitory, closing calcium channels and reducing 
neurotransmitter release from the neuron whose receptors they bind to (Di Marzo et al., 
1998; Kreitzer & Regehr, 2001). The inhibitory activity of endocannabinoids is 
terminated by monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase 
(FAAH), which are enzymes that break down excess endocannabinoids in the pre- and 
post-synaptic terminal (Keimpema et al., 2010). With correct timing and quantity, this 
typically keeps the system in balance.  
The default continuous signaling of the endocannabinoid system generally 
results in a baseline inhibition of the HPA axis (Hill et al., 2011). Specifically, the stress 




endocannabinoids. These endocannabinoids bind to CB1 receptors in the PFC that lead 
to inhibition of the HPA cascade (Hill et al., 2011). The prefrontal cortex’s inhibition of 
an active HPA axis leads to fewer stress hormones being released downstream.  
The endocannabinoid system is, thus, heavily involved in the modification of 
anxiety. The typical functioning of the endocannabinoid system in this manner is 
important for several functions including extinguishing emotionally-charged content 
like fearful memories (Chhatwal et al., 2005; Pamplona et al., 2006). Increasing 
endocannabinoids by blocking natural degradation results in decreased anxiety in 
response to environmental stressors or stressful social isolation in rats (Kathuria et al., 
2003). Likewise, introducing cannabinoid antagonists that block the functions of 
endocannabinoids increases anxious behaviors in rats (Arevalo et al., 2001). The 
anxiolytic effects of enhanced endocannabinoid receptor activation are likely reasons 
that individuals find it pleasurable to use cannabis recreationally.  
Under chronic stress, the release of an abundance of glucocorticoids (e.g., 
cortisol) can lead to a downregulation of the endocannabinoids, which are then unable 
to naturally excite the inhibitory neurons in the prefrontal cortex and halt the stress 
cascade (Hill et al., 2011). This consistently uninhibited HPA axis is characteristic in 
disorders like anxiety and depression (Riebe & Wotjak, 2011).  A higher concentration of 
stress hormones sustained over time represents a hyperactive HPA axis that has not 
been appropriately regulated by the endocannabinoid system. This may indicate a 
problem with the HPA axis itself or with the endocannabinoid network that interacts 




Studies have consistently demonstrated increased cortisol levels in association 
with chronic symptoms of anxiety. Higher morning concentrations of cortisol (the 
cortisol awakening response) were observed in adults with current active anxiety 
disorders, particularly panic disorder and anxiety disorders with comorbid depression 
(Vreeburg et al., 2010). In pediatric populations, increases in the cortisol awakening 
response over several years predicted a higher, more sustained level of cortisol in 
response to a stressful event (Laurent et al., 2015). In adolescent populations, this same 
association was observed, and high morning cortisol levels actually predicted who 
would develop an anxiety disorder six years later (Adam et al., 2014). In response to a 
stressor, those with anxiety typically display a flatter recovery slope in adulthood, 
sustaining high cortisol levels for longer periods of time (Fiksdal et al., 2019). These 
studies suggest that those with anxiety disorders, or a vulnerability to develop one, 
display abnormal patterns of cortisol concentrations.  
DHEA is another main end-product of the HPA axis. Besides being a precursor 
for various sex hormones, DHEA can influence mood and response to stressors by 
directly acting on various excitatory NMDA receptors as well as inhibitory GABA 
receptors (Bergeron et al., 1996; Maninger et al., 2009). Mouse models have 
demonstrated that DHEA can increase the action of inhibitory GABA receptors in the 
nucleus accumbens and ventral tegmental area, which has been found to produce 
antidepressant effects (Genud et al., 2007). Thus, according to these researchers, DHEA 
is being explored for its potential role as a treatment for mood disorders. DHEA has 




of cortisol on neural systems, promoting neuronal survival following injury 
(Lennartsson et al., 2012; Van Voorhees et al., 2014). This is accomplished by blocking 
excitotoxicity, specifically NMDA toxicity, in brain regions like the hippocampus 
(Kimonides et al., 1998).  
Although it would seem that higher DHEA concentrations would provide a 
neuroprotective advantage, this may not always be the case. While certain levels of 
DHEA can be neuroprotective, higher concentrations may be ineffective or even 
neurotoxic to the organism (Maninger et al., 2009). In early controlled experiments by 
Kimonides and colleagues (1999), the highest concentrations of DHEA led to mildly 
neurotoxic effects within the hippocampus. In addition to having neurotoxic effects, 
neuroprotective effects on memory were observed at moderate concentrations of 
DHEA, but at low and high concentrations DHEA, was less effective (Flood et al., 1988). 
In regard to long-term emotional dysregulation, higher concentrations of DHEA or 
DHEA-to-cortisol ratios have been reported in those with anxiety disorders, such as 
PTSD and panic disorder, demonstrating an association between the functioning of the 
HPA axis and problematic anxiety (Brambilla et al., 2005; Pico-Alfonso et al., 2004; Van 
Voorhees, 2014; Yehuda et al., 2006).  
Given that increased concentrations of cortisol and DHEA are associated with 
anxiety symptoms, these early measurements may serve as an important predictor of 
future mood and anxiety disorders. Furthermore, deviations in typical cortisol and 
DHEA concentrations may be detectable as early as infancy. During typical functioning, 




as not to secrete unnecessarily high concentrations of glucocorticoids but still maintain 
the ability of the organism to respond appropriately to new stressors (Hill, 2010). It is 
crucial that the system is able to adapt in this manner, because persistent secretion of 
stress hormones can have harmful effects on several body systems. Early detection of 
poor HPA regulation, as measured through high concentrations of cortisol and DHEA, 
may offer insight into what can contribute to emotion regulation difficulties at later time 
points in development.  
 
“Exogenous cannabinoids:” the influence of THC on the endocannabinoid system 
Many active chemicals are found in marijuana, but, generally, delta 9-
tetrahydrocannabinol (THC) is the most widely recognized for its activity within the 
brain. THC is the only mood-altering cannabinoid identified in the cannabis plant and 
is generally an agonist of endocannabinoid CB1 receptors distributed throughout the 
brain (Mechoulam et al., 2013). However, in some brain networks where there are low 
densities of CB1 receptors, THC can serve as an antagonist, competing with the 
endocannabinoid 2-AG at CB1 receptors and blocking the effects of the 
endocannabinoid system (Lu & Mackie, 2016). This is because, in some systems, THC is 
a low efficacy agonist at the CB1 receptors, which can compete with the high efficacy of 
2-AG at the same receptors. In other brain systems, THC acts with high efficacy at the 
CB1 receptors. Therefore, the influence of THC is not always straightforward, and this 
may explain why cannabis use can sometimes have conflicting effects on the user.  




endocannabinoids (Di Marzo et al., 1998). Similar to endocannabinoids, THC can 
decrease amygdala reactivity in the presence of threatening stimuli via activation of 
CB1 receptors and can strengthen the connectivity between the amygdala and regions 
like the prefrontal cortex (Banks et al., 2007; Gorka et al., 2015). Enhanced connectivity 
between these regions is typically associated with better affect regulation and control of 
the HPA axis.  
Despite generally being able to mimic the anxiolytic effects of endocannabinoids 
via similar inhibition of the stress response cascade, there is some conflicting evidence 
regarding the effects on the HPA axis. For instance, in mouse models, THC or synthetic 
analogs have also repeatedly been shown to increase adrenocorticotropic hormone 
(ACTH) and corticosterone levels, an equivalent of cortisol in mice (Murphy et al., 
1998). ACTH can lead to the release of more corticosteroids (cortisol), which can initiate 
the inhibitory pathway associated with the prefrontal cortex. But if corticosteroids are 
released in too large of an amount, they can have a neurotoxic effect on the stress 
response system, leading to a downregulation of the natural endocannabinoids, which 
damages the system of checks and balances. Timing and duration of exposure can also 
alter this association. Murphy and colleagues (1998) demonstrated that THC’s enhanced 
activation of ACTH and cortisone release in rats stopped after continual administration 
of THC for a week. This effect varied depending on the species studied within a given 
research paradigm. For instance, in monkeys, this blunting effect was not observed as 
strongly (Bailey et al., 1990). Elevated cortisol levels in response to THC were observed 




hormone levels has not been tested directly in human fetal HPA systems, so the 
influence of THC at that specific time point remains to be seen. However, these 
experiments demonstrate that THC can impact the HPA axis in different and sometimes 
conflicting ways, and further work is needed to specifically assess the influence on the 
fetal HPA axis.  
Generally, the endocannabinoid system appears to play a role in reducing 
anxious responses, but one of the most puzzling inconsistencies in the literature on 
adult cannabis users concerns whether acute use of cannabis has an anxiety-reducing or 
anxiety-producing effect. The answer to this question is important for understanding and 
predicting whether prenatal cannabis exposure may heighten or decrease anxiety and 
the stress reactivity in offspring. It may also be useful for explaining conflicting findings 
regarding THC’s influence on the HPA axis. Studies involving adult self-reports 
indicate that both anxiety-producing and anxiety-reducing effects are possible (Ilan et 
al., 2005; Metrik et al. 2011).  
Dose is hypothesized to play a major role in determining whether acute exposure 
to cannabis is anxiolytic or anxiogenic, with higher doses generally producing 
heightened fearfulness in stress-inducing situations and lower doses generally reducing 
anxious responses (Navarro et al., 1997). This was confirmed again more recently in an 
experiment in which cannabinoid agonist injected directly into the prefrontal cortex of 
rats led to an anxiolytic effect in moderate doses and an anxiogenic effect in larger doses 
(Rubino et al., 2007). These findings raise important questions related to dosage that are 




be vulnerable to the influence of THC, and they are discussed in the prenatal cannabis 
exposure section that follows. The anxiogenic/anxiolytic effects in the aforementioned 
studies were observed acutely rather than being studied long-term. Therefore, 
investigating whether prenatal cannabis exposure may have lasting, long-term effects 
on stress reactivity/emotional functioning is also very important. 
A meta-analysis by Kedzior and Laeber (2014) demonstrated a positive 
association between cannabis use and anxiety disorders in the general population, 
although the direction of the association is not clear. The researchers found that baseline 
cannabis use was positively correlated with high anxiety at follow-up across several 
studies. Although cautious about saying that cannabis use caused an anxiety disorder, 
they offer the possibility that cannabis use could exacerbate pre-existing anxious 
symptomology. Likewise, it may be possible that prenatal cannabis exposure could 
exacerbate pre-existing biological vulnerabilities in the fetus related to stress reactivity 
and that these changes may be permanent since they are occurring during key points in 
neurodevelopment.  
Regardless of directionality (anxiolytic vs. anxiogenic), it is clear that cannabis 
acts on the biological substrates associated with anxious responses. Given the integral 
role of endocannabinoids in regulating the HPA axis, anything that can affect the 
efficacy or availability of the natural endocannabinoids, can change the stress response 







The endocannabinoid system is critically important for the proper functioning of 
the stress response system. Direct cannabis exposure has the ability to change hormonal 
responses to stress via modulation of the hypothalamic-pituitary-adrenal axis. 
However, given that the HPA axis is being developed during gestation, the way that 
prenatal cannabis may influence this fragile and dynamic system is less clear but may 
mirror what has already been observed in adult populations. The next section will focus 
on what we know about the fetal endocannabinoid system, the early stress response 




Prenatal Cannabis Exposure 
 
Statistics/Legalization Concerns 
Cannabis is widely used by women of child-bearing age and is frequently used 
during pregnancy. Data from national surveys on drug use revealed that in 2014, 3.9% 
of pregnant women surveyed reported cannabis use within the previous month (Brown 
et al., 2017). Given concerns of under-reporting due to social desirability bias, in 2017 
researchers Young-Wolff and colleagues sampled approximately 280,000 pregnant 
women in California using self-report measures as well as hospital toxicology 




use during pregnancy increased from 4.2% to 7.1% in their sample. This rate was much 
higher for younger pregnant females in this cohort: 19-22% for those under 25 years old. 
During the years that this study took place, medical cannabis was legalized in the state 
of California. With the extension of legalization into other states beyond California, the 
rate of prenatal exposure may further increase in the future. Similarly, data from the 
National Survey on Drug Use and Health determined that rates of cannabis use by 
pregnant women in the United States from 2002-2017 increased from 3.4% to 7% 
(Volkow et al., 2019). 
In correspondence with the increase in use, public opinion generally views 
cannabis as benign. Survey responses from over 93,000 women between 2007 and 2012 
indicated that almost 70% believed that there is little or no harm using cannabis weekly 
(Ko et al., 2015). In fact, a meta-analysis by Bayrampour et. al (2019) confirmed that 
pregnant women often don’t perceive risks associated with cannabis use and interpret 
the general lack of warning from healthcare providers as a sign of its safety. These 
views regarding safety could have important societal impact when considering 
potential generational issues associated with increased rates of prenatal exposure.  
 
Longitudinal emotional outcomes of children exposed in utero 
Given recent public opinion, it is unclear whether research supports or refutes 
the safety of cannabis at the prenatal level. Does potential harm increase or decrease 
exposure of the embryo/fetus in utero compared to direct exposure of adults? Few 




functioning in infants and children, who are not using cannabis directly, but have been 
exposed during their prenatal development via maternal drug use. A handful of 
prospective longitudinal studies exist that have been measuring the outcomes of 
prenatal exposure to many common substances of abuse, including cannabis (Huizink, 
2014).  
The Ottawa Prenatal Prospective Study (OPPS) began in 1978 and followed 
mostly middle-class Caucasian pregnant women. Following this study, the Maternal 
Health Practices and Child Development Study (MHPCD) was initiated in 1982, and 
followed high risk/low SES women of mixed ethnicity. The National and Maternal and 
Infant Health Survey (NMIHS) was administered in 1988, and this survey was followed 
up longitudinally in 1991. The most recent longitudinal study, the Generation R study, 
began in 2001 and has been following a multiethnic population with slightly higher 
socioeconomic status than the MHPCD study. Many publications concerning the effects 
of in utero cannabis use on human offspring have come from these longitudinal studies. 
While many publications have focused on the negative impact of prenatal exposure on 
outcomes, such as offspring birth outcomes, cognitive development, and motor skills, 
very few have specifically investigated offspring emotional development. Of those that 
did, observation of subtle deviations in the early behaviors of exposed newborns have 
suggested limbic system alterations secondary to prenatal cannabis exposure. 
As early as the perinatal period following birth, an exaggerated and prolonged 
startle response was observed in newborns included in the OPPS study who were 




Neonatal Behavioral Assessment Scale, which includes behavioral ratings and 
characterizes elicited responses (reflexes, responses to stress, etc.). During this early 
developmental time period, exposed newborns also exhibited higher jitteriness, a more 
pronounced motor reflex, and decreased habituation to visual stimuli than unexposed 
newborns. The heightened startle response of these newborns may be indicative of 
altered biological development in the prenatal and post-natal periods. For instance, 
recent imaging studies have linked heightened infant fearfulness (not specifically 
related to prenatal substance exposure) to stronger amygdala connectivity (Graham et 
al., 2016). Given what we know about the distribution of CB1 receptors in the amygdala, 
prenatal cannabis’ influence on the endocannabinoid receptors in this brain region may 
explain the early heightened startle observed in exposed infants.  
Similarly, in a study from a Brazilian hospital, cannabis-exposed newborns 
evinced heightened initial sensitivity, which was characterized by higher arousal and 
excitability and lower regulatory abilities (De Moraes Barros et al., 2006). The prenatal 
cannabis exposure was well documented in offspring via positive meconium results, 
and the significant findings corroborate initial evidence from other research groups of a 
biological difference in reactivity in exposed newborns.  
While this behavioral evidence is compelling, in and of itself, an imaging study 
investigating prenatal substance exposure found early differences in brain connectivity 
in networks associated with limbic function (Grewen et al., 2015). Prenatal substance 
exposure, including cannabis, was associated with significantly greater connectivity 




weeks old. Given the prefrontal cortex’s important role in exerting inhibitory control 
over emotional responses of the amygdala and the HPA axis, this early hyper-
connectivity may contribute to the risk of developing future emotion regulation 
difficulties. Previous research with adult cannabis users demonstrated a similar increase 
in connectivity between the amygdala and the prefrontal cortex but was interpreted as 
potentially favorable (Gorka et al., 2015). Specific to prenatally exposed children, under-
connectivity was observed between right caudate and right fusiform gyrus, which the 
researchers suggested may put a child at risk for future emotional difficulties related to 
social-emotional processing given the role of the fusiform gyrus in facial recognition. 
Given early heightened startle response and early evidence of fiber tract 
deviations relevant to emotion regulation, heightened emotional sensitivity to threat 
would be likely to emerge across later development as well. Indeed, maternal reports of 
their three-year-old infants in the National Maternal and Infant Health Survey study 
indicated heightened fearfulness in cannabis-exposed toddlers (Faden & Graubard, 
2000). This study demonstrated a dose-dependent relationship; as the amount of 
prenatal cannabis exposure increased, so did the later levels of infant fearfulness. 
Although this study relied predominantly on maternal report of infant behaviors, the 
results align with the hypothesis from earlier developmental time points. This finding 
of increased fearful infant behaviors importantly corroborates the finding of hyper-
connectivity between the prefrontal cortex and amygdala, and serves as another early 





Fear in infancy is predictive of fearfulness and lower approach behaviors later in 
life (Rothbart et al., 2006) and, thus, would likely be seen at older ages as well. Indeed, 
cannabis-exposed children in the MHPCD study self-reported significantly higher 
levels of depressive symptoms at the age of 10 (Gray et al., 2005).  Effects on child mood 
were trimester-specific, largely being explained by first trimester exposure in this study. 
No other illicit substance exposure (e.g. cocaine, etc.) was significantly associated with 
depressive symptoms, although prenatal exposure to tobacco and alcohol, and high 
maternal stress were. This study did not assess clinical diagnoses of depression, but 
even if subclinical, the significantly higher number and severity of depressive 
symptoms reported imply a difference in sensitivity to negative events and emotion 
regulation abilities within the limbic system. It remains to be determined what 
percentage of children from this study with elevated subclinical scores at age 10 
develop a mood disorder later in adolescence/adulthood. However, this is not to say 
that these early subclinical depressive symptoms are innocuous. To illustrate, the 
negative effect of first trimester cannabis exposure on depression and anxiety 
symptoms at age 10 was determined to mediate weaker academic achievement in 
exposed children, thus offering one example of associated functional impairment 
(Goldschmidt et al., 2004).  
Based on this early behavioral research in infants and children, prenatal cannabis 
exposure seems to influence emotional development by heightening early reactivity, 
increasing early fear responses, and, over time, resulting in mood disturbances that can 




emotional functioning could make offspring vulnerable to later addiction and 
psychiatric disorders. Indeed, a correlational study by researchers Porath and Fried 
(2005), using longitudinal data from the Ottawa Prenatal Prospective Study, 
documented a dose-response relationship between early prenatal cannabis exposure 
and the use of cigarettes and cannabis in adolescence. These authors offer a potential 
explanation that prenatal exposure sensitizes the developing brain to the later influence 
of cannabis. They also cited the activation of mesolimbic dopamine pathways in 
response to cannabis as a potential mechanism that leads to later drug-seeking 
behaviors.  
Only one study found better emotional functioning in cannabis-exposed 
offspring. This early study by Dreher et al. (1994) was conducted ethnographically in 
Jamaica and compared 24 exposed newborns to 20 unexposed. These researchers used 
the same scale that Fried and Makin (1987) used, the Brazelton Neonatal Behavioral 
Assessment Scale, but instead of finding poorer habituation, higher irritability, and 
increased tremors/startles in exposed newborns, the neonates in their sample actually 
displayed the opposite outcome. At one-month old, these newborns showed better 
physiological stability. In fact, the offspring of heavy cannabis users had better 
autonomic stability, quality of alerting, irritability, and self-regulation at this age.  
These two studies assessed newborns at different postnatal time points. When 
collapsing them together into one developmental timeline, Dreher et al. (1997) found no 
difference in reactivity or regulation when the neonates were one day old, Fried and 




Dreher and colleagues provided evidence of better outcomes when the exposed 
newborns were one-month old.  It is possible that at different points, the effects of 
prenatal exposure may lead to differing behavioral outcomes, or it is possible that these 
two cohorts were characteristically different in ways that resulted in conflicting 
outcomes. Furthermore, neither study assessed whether breastfeeding mothers were 
continuing to use cannabis, and this secondary exposure may explain some of these 
differences as well.  
These few aforementioned studies represent the extent of the very limited 
emotion regulation/stress response research in prenatally-exposed human offspring 
that existed up until 2021. Although the longitudinal studies of exposed children 
frequently publish findings related to cognition and externalizing behaviors, very little 
attention has been paid to the interplay between prenatal cannabis exposure and 
emotional development with regards to the HPA axis. Several animal studies have 
complemented the sparse findings in humans. These studies have allowed for more 
careful and deliberate control over the degree of cannabis exposure and have allowed 
for measurements that would be unethical to utilize in human children.  
Animal models of prenatal cannabis exposure have demonstrated early 
deviations in the stress response of exposed offspring that were often maintained across 
development. Researchers Trezza et al. (2008) administered doses of THC to pregnant 
rats that were equivalent to moderate human cannabis consumption. The pups born to 
mothers who received the THC doses during pregnancy demonstrated increased 




made when removed from their nest. In addition to these early deviations, in 
adolescence, the offspring demonstrated inhibited social interaction, spending less time 
playing, and in adulthood, demonstrated anxious behaviors when engaged in an 
elevated plus-maze, including a lower percentage of time spent in the open arms of the 
maze (a sign of anxiety in mice). Prenatally-exposed pups demonstrated dose 
dependent variations in the number of cries they emitted when removed from their 
nest, with a higher prenatal THC dosage resulting in a greater number of cries. The 
same was true for the other measures of anxiety; social interactions and time spent in 
the open arm of the maze were inversely related to amount (dosage) of prenatal 
exposure.  These researchers also demonstrated that, depending on timing and 
frequency of prenatal exposure (which trimester and acute vs. chronic administration) 
and type of substance (THC vs. synthetic cannabinoid agonist), the opposite effect on 
offspring anxiety may be observed. For instance, when mothers were administered a 
lower dose of synthetic cannabis daily from gestational day 5 to 20 (corresponding to 
human trimesters 1 & 2), the prenatally-exposed pups demonstrated a significantly 
reduced number of cries when removed from their nest (Antonelli et al., 2013). Possible 




To summarize these findings across both human and animal studies, offspring 




several developmental time points. This emotional dysregulation, resulting from 
passive exposure secondary to maternal use, is similar to the findings in both rats and 
human adults who were directly exposed to cannabis or synthetic equivalents. 
Although the outcome appears similar, the internal biological system on which the 
active chemicals in cannabis work, are set up differently in a fetal brain as opposed to 
an adolescent or adult brain. Additionally, higher doses of prenatal exposure appeared 
to increase resulting anxiety in offspring. To understand mechanistically how prenatal 
cannabis exposure may be producing the later deviations in emotional functioning 
observed in exposed children, it is critical to understand early development of the stress 
response systems in utero, as well as the mechanisms and functions of the endogenous 
endocannabinoid system as it relates specifically to prenatal development.  
 
How do endocannabinoids work in utero?  
The naturally occurring endocannabinoid system plays a major role in early 
neurodevelopment. Cannabinoid receptors, predominantly CB1 receptors, begin to 
develop in the fetal brain at early time points and increase in density through the third 
trimester (Wang et al., 2003; Wang et al., 2004). Early in gestation, these CB1 receptors 
are highly expressed in important mesocorticolimbic structures, namely the amygdala, 
hippocampus, and the ventral striatum, and are fully functional (Wang et al., 2003). 
Endocannabinoids are thought to help with gestational growth and establishing 
neuronal circuits in the brain (Harkany, 2007). The role of this endogenous cannabinoid 




and synaptic plasticity during these early periods of brain growth and maturation 
(Aguado et al., 2006; Berghuis et al., 2007; Howlett et. al, 2002; Jutras-Aswad et al., 2009; 
Oudin et al., 2011; Williams et al., 2003). These functions allow the endocannabinoid 
system to play a later role in cognition, memory, and emotional processing. In addition 
to cannabinoid receptors, dopaminergic cells are also detected early in gestation and 
can be present by the fifth week of development (Verney et al., 1991).  
Endocannabinoid concentrations, particularly for anandamide, increase during 
the embryonic phase and are heavily involved in early fetal brain development 
(Berghuis et al., 2007). Levels then decrease during mid-gestation and remain lower 
until birth. Endocannabinoids are required for the correct set-up of brain circuits during 
fetal development. Activated CB1 receptors can influence the path of growth cones, 
acting as axon guidance cues that lead to new synapses and connections (Berghuis et al., 
2007). As previously mentioned, monoacylglycerol lipase (MAGL) is an enzyme that 
breaks down excess endocannabinoids. Once a neuron has stabilized in its intended 
location and form, MAGL is released in order to eliminate unwanted outgrowth 
(Keimpema et al., 2010). It accomplishes this stability by eliminating extra anandamide 
from the system. If prenatal exposure to exogenous cannabinoids can mimic the 
function of anandamide and other endocannabinoids, this has the potential to cause 
unwanted growth and movement of different neurons during crucial early 





How does prenatal cannabis exposure specifically affect the brain/alter the infant HPA 
system?  
THC is lipophilic in maternal blood plasma and is able to cross the placenta and 
interact with the developing offspring’s neurocircuitry. Hutchings and colleagues (1989) 
utilized rat models to determine this relationship, and in their study, higher doses and 
frequency of doses resulted in higher plasma concentrations of THC in the mothers. 
THC plasma concentrations in the fetus were approximately 10% of those found in the 
mother and increased in the fetus in a dose-dependent manner. Other researchers 
utilizing rhesus monkey models also identified a rapid transfer of THC from mother to 
fetus (Bailey, 1987). In this study, peak THC concentrations were achieved in the mother 
15 minutes after drug administration and less than a tenth of that THC concentration 
was found in fetal plasma. However, after three hours, the maternal and fetal plasma 
THC concentrations were equivalent, indicating that although the peak fetal plasma 
concentrations are lower compared to the mother’s, THC gets cleared from the adult 
plasma at a faster rate than from the fetal plasma. Despite these two early studies, the 
literature on the placental transfer of THC is surprisingly insufficient and dated. 
Although there is no debate that THC from the mother can reach the embryo/fetus, the 
extent to which the placenta filters THC out, especially in human models rather than 
animal models, remains to be determined. Overall, exposure to cannabis via the mother 
during pregnancy can reach the developing fetus and, based on previously presented 




During critical periods of fetal development, the stimulation of the cannabinoid 
or the related dopaminergic receptors via THC exposure may significantly alter 
development by potentially changing neuronal signaling, resulting in aberrant brain 
circuitry (Jutras-Aswad, 2009). Although THC can function like endocannabinoids by 
activating the CB1 receptors in a similar fashion, MAGL and other enzymes that 
degrade endocannabinoids are not able to eliminate THC the way they can with 
endocannabinoids (Kim et al., 2001). Therefore, introducing THC to developing 
neurocircuitry in utero could result in erroneous activation of CB1 receptors, leading to 
undesired neuronal outgrowth, including synapse formation errors. Additionally, the 
presence of THC, itself, can increase production of endocannabinoids in a dose-
dependent fashion, leading to a higher concentration than necessary (Burstein et al., 
1994). In addition to increasing endocannabinoids and being impervious to 
degradation, THC exposure can desensitize CB1 receptors, compete against natural 
endocannabinoids, and downregulate receptor availability even in relatively short 
periods of time (Coutts et al., 2001). All of the aforementioned changes can lead to long-
term functional modification to cortical circuitry following prenatal cannabis exposure 
(Tortoriello et al., 2014). Therefore, prenatal THC exposure can lead to the unnatural, 
unplanned, and indiscriminate activation of CB1 receptors, thus potentially changing 
endocannabinoid signaling. 
Dopaminergic neurons contain CB1 receptors and are influenced by the 
cannabinoids that bind with these receptors. The dopamine system in brain structures 




exposure (Dinieri, et al., 2011; Wang et al., 2004). Reduced dopamine (D2) receptor 
mRNA levels have been found in the nucleus accumbens (Dinieri et al., 2011) and 
amygdala (Wang et al., 2004) of exposed human fetuses, which are areas important for 
emotional regulation. In animal models, initial decreases in the quantity of D1 receptors 
were observed in the mesolimbic brain regions of exposed female rat offspring (De 
Fonseca et al., 1991). These changes may be yet another biological driving force behind 
observed emotional difficulties in exposed offspring and are the only reported changes 
observed in human fetuses.  
With regard specifically to HPA development and function, during the second 
and third trimester of human fetal development, the fetal adrenal gland develops a 
specialized zone that only exists in utero and atrophies after birth (Johnston et al. 2018). 
The “fetal zone,” as it is called, produces large quantities of DHEA and cortisol 
throughout gestation, which assists with processes like the maturation of fetal organs. 
Cortisol is detectable in fetal plasma as early as the second trimester, and concentrations 
generally remain stable throughout development in utero (Johnston et al., 2018). The 
fetal adrenal gland begins to produce hormones like DHEA around the 8th-10th week 
of gestation (Mesiano & Jaffe, 1997). Across the lifespan, DHEA concentrations typically 
decline from the first month of life to around age five and then rapidly increase at 
around 7-9 years old (Sulcová et al., 1997). The age at which this rapid increase occurs 
depends on the child’s sex, typically occurring at a younger age in girls.  
Given the observed stress response modification due to direct exposure in 




exposed human fetuses, it is reasonable to hypothesize that prenatal exposure in 
humans may change the early developing stress response system in measurable ways. 
Despite the growing evidence of emotional dysfunction in exposed offspring, when 
beginning this research study, there were no published research studies that 
investigated possible early alterations in the stress response system in prenatally-
exposed human infants in vivo. Although studies conducted in humans cannot be done 
with the same molecular specificity as animal studies, alternative approaches can be 
used. These involve assessments of a direct, physiological stress response or can involve 
measuring downstream products of the stress response system in specimens like saliva 
or hair. Exposure during critical processes occurring in utero may lead to alterations in 
neurocircuitry that would cause chronically high or low levels of stress hormone 
concentrations that can be measured in biological samples (McEwen, 2004).  
A very recent study by Cajachagua-Torres et al., published online in May 2021 
followed the cohort of children studied in the previously discussed Generation R study. 
Their results demonstrated that prenatal cannabis exposure was associated with 
significantly higher cortisol concentrations in early childhood. They, additionally, 
explored whether other variables besides the cannabis exposure could explain the 
observed cortisol elevation. Birthweight was a proposed explanation for this 
relationship but was found to not be a mediator between drug exposure and cortisol 
levels. Cannabis use by mothers before pregnancy also did not appear to be associated 
with differences in cortisol. Further, sociodemographic factors and paternal substance 




deviations in cortisol levels, isolating the specific influence of cannabis. Therefore, it 
was suggested that prenatal cannabis exposure, itself, may have a direct effect on the 
fetus. This novel study offers a first-time glimpse specifically into early HPA axis 
deviations in children as young as 6 years-old.  
 
Overall limitations of previous studies 
As just mentioned in the Cajachagua-Torres et al., 2021 study, some participants 
in the study were also exposed to tobacco in utero. Polysubstance use is extremely 
common in naturalistic studies with human subjects and remains a general limitation 
that is pervasive across the substance abuse literature because of the difficulty isolating 
the contributions of each drug separately. For instance, Chabarria et al. (2016) found 
that in their sample of pregnant cannabis users, comorbidity of both cannabis and 
tobacco use was almost 45%. The impact of the active chemicals in tobacco at the 
nicotinic receptors can possibly mirror, amplify, or reverse the risks associated with 
cannabis exposure alone. Polysubstance exposure should be carefully controlled for in 
studies and limited whenever possible if the goal is to investigate the direct effects of 
cannabis alone.  
In addition to multiple potential substance exposures, substance users who 
enroll in research studies on drug use often have higher rates of psychiatric 
comorbidities than those in the control groups. These comorbidities can make them 
more prone to transfer biological vulnerabilities to their offspring. This has rarely been 




of Faden and Graubard (2000) where cannabis exposure was associated with higher 
levels of infant fearfulness, these researchers controlled for several maternal 
demographic factors, but there was no assessment of maternal anxiety or stress during 
pregnancy. It is possible that higher levels of maternal anxiety were associated with a 
higher likelihood of using cannabis both generally and specifically during pregnancy. 
With that in mind, the biological underpinnings of maternal anxiety may be the risk 
transferred to the fetus, rather than changes because of cannabis exposure itself. Poor 
prenatal care can, unfortunately, also be common in substance-using mothers and 
difficult to control for. Adverse parenting issues may additionally alter 
neurodevelopment or exacerbate biological vulnerabilities in a way that is also difficult 
to separate from the substance exposure itself.  
Methodologically, many previous behavioral outcome studies have directly 
assessed children only as newborns or later in childhood. Of the studies reviewed in the 
previous sections, anxiety and stress response have only been assessed directly in 
newborns and at the ages 6 and 10, leaving a critical gap in infancy. Although 
assessment of toddlers must frequently rely on parental reports of behavior until the 
child is able to report symptoms and behaviors on their own, this can be circumvented 
by directly collecting biological markers of stress, as done in the recent Cajachagua-
Torres et al. (2021) study with 6-year-olds. Despite this recent study, there remains a 
critical gap in the literature for measuring possible HPA axis deviations at earlier time 




An additional methodological limitation pertains to the lack of control and 
potential accuracy that researchers have over the timing and dosage of cannabis 
exposure. This is an inherent design flaw in most studies of substance use in humans in 
which studies often cannot accurately account for the amount of cannabis used, its 
potency, the exact timing of use during the pregnancy, etc. This can result in flawed 
group assignments and analysis limited to inter- rather than intra-group differences.  
Lastly, there exist conflicting findings when comparing results of the Fried and 
Dreher studies, which may be partly explained by the rat studies conducted by Trezza 
and colleagues. In Trezza et al. (2008), manipulations of dose and type of exposure 
resulted in contrary outcomes, either enhancing or decreasing anxious behaviors in 
exposed offspring. In this way, given that most studies do not have accurate accounts of 
intensity and frequency of exposure, two offspring put together in the same “exposed” 
category may have opposite neurobehavioral outcomes. Because of large within-group 
variability, the effects of prenatal cannabis may be difficult to ascertain, given that 
opposing effects could negate any meaningful group differences.  
 
Conclusion 
Stimulation of the cannabinoid or related dopaminergic receptors during crucial 
periods of fetal development can significantly disrupt typical developmental pathways. 
Disruption of prenatal neurobiological processes, may cause lasting biological changes 
that enhance future susceptibility to various neuropsychiatric conditions (Morris et al. 




stress hormone levels may predict observed increases in traits like early infant 
reactivity. An inappropriately heightened stress response can translate into a difficult 
infant temperament, and a difficult infant temperament may further lead to behavior 
problems and diagnosed psychopathology later in childhood and adolescence (Lester et 
al., 2009). Specifically, early biological alterations could make offspring vulnerable to 
later anxiety disorders (Porath et al., 2005). Given the increasingly favorable public 
opinion towards cannabis and recent legislative changes in legalization, knowledge of 
early deviations is critical in order to inform public health practices surrounding 
pregnant women and their offspring. Information regarding human infants’ in vivo 
HPA axis would offer valuable evidence of biological alterations that could potentially 
















Hypothesis 1: Cajachagua-Torres and colleagues’ study (2021) demonstrated that 
prenatal cannabis exposure was associated with significantly higher cortisol 
concentrations at the age of 6. It stands to reason that the results of their study can be 
extended to younger age groups as well. Prenatal exposure to cannabis likely leads to a 
cascade ending with chronically elevated cortisol, and this effect would be observed as 
early as infancy. A blunted cortisol response would not be anticipated so early in 
development. A similar elevation would also be expected in DHEA concentrations.  
Hypothesis 2: Although birthweight was previously found not to mediate the 
association between prenatal cannabis exposure and glucocorticoid concentrations, it is 
hypothesized that the effect of cannabis exposure in altering HPA function might 
depend on variables that stand for global optimal development among infants, such as 
birthweight. While we recognize that birthweight is influenced by a myriad of other 
factors, it is a convenient measure and has been utilized by many researchers as an 
indicator of fair development. Therefore, a significant interaction is predicted where the 
negative effect of in utero exposure to cannabis varies depending on the biological 
resilience of the host. Likewise, maternal anxiety during pregnancy has a likely 
influence on infant HPA functioning. A significant interaction between maternal 
anxiety and prenatal cannabis exposure is similarly predicted.  
Hypothesis 3: Elevated anxiety levels in offspring would likely be associated with 









Overview. The data used for this study comes from a larger study investigating 
prenatal factors that predict infant outcomes, with an emphasis on stress in pregnancy.  
The participating families were initially recruited from two major hospitals in New 
York City during the second trimester of pregnancy. The Institutional Review Boards at 
City University of New York, Queens College, New York Presbyterian Queens, and 
Icahn School of Medicine at Mount Sinai approved this project, and the participating 
parents gave their informed consent. Details of the research protocol and of the 
recruitment of the initial sample can be found in Finik and Nomura (2017). 
 
Inclusion and exclusion criteria for study participants. Maternal psychosis, age 
<15 years at time of child’s birth, HIV infection, and life-threatening medical 
complications were exclusionary criteria. Fetuses with congenital or chromosomal 
abnormalities were also excluded from the study. A subsample of 257 infants, who 
completed their first specimen collection of hair samples between the ages of 1 and 5 
years, was included in the current study. Of the 257 infant-mother dyads eligible to be 
included in this sub-study, 10 participants were excluded due to prenatal cocaine 
exposure during the pregnancy. A total of 241 participants had one or both hormone 




the current study (N=241) and those active participants of the parent study without hair 
samples or without at least one hormone value within acceptable range were not 
significantly different across child gender, maternal age, marital status, maternal 
education, or race. 
 
Determination of prenatal exposure status. Maternal substance-use during pregnancy 
for cannabis, tobacco, alcohol, and cocaine was assessed via self-report and a review of 
social worker records from the pregnancy. Prenatal exposure was coded as a binary 
variable (yes/no). When information about frequency was available, this was included.  
 
Demographics and maternal characteristics. Demographic information, including child 
gender, race, and age at time of hair collection, as well as maternal age at birth of child, 
education level, and marital status, were obtained after consent. Birth outcomes 
including birth weight and gestational age, were assessed via a review of hospital 
medical records and maternal self-report.  
 
Maternal pathology (lifetime and pregnancy-specific). Mothers completed five self-
report scales of anxiety, depression, and stress: the State-Trait Anxiety Inventory, The 
Edinburgh Postnatal Depression Scale, the Perceived Stress Scale, the Pregnancy 
Related Anxieties Questionnaire-Revised, and the Psychiatric Epidemiology Research 




The 40-item State-Trait-Anxiety Inventory (STAI) was the predominant measure 
of maternal anxiety used in the current study. It is designed to assess transient, 
temporary emotional states representing “state anxiety” and more long-term, 
generalized proneness to repeatedly experience anxiety, representing more of a 
personality factor or “trait anxiety” (Spielberger et al., 1983). Each state and trait 
subscale has 20 items each, rated on a 4-point scale (from 1-“Almost Never” to 4-
“Almost Always”). The scores are summed to create a subscale score ranging from 20-
80, with higher scores representing greater symptoms of anxiety. The state anxiety 
subscale includes statements like “I am tense” or “I feel upset” and the trait anxiety 
subscale includes statements like “I worry too much over something that really doesn’t 
matter” or “I lack self-confidence.” The STAI has good internal consistency greater than 
.89, and average test-retest reliability over a two-month period was .88 for trait anxiety 
(Barnes et al., 2002).  
The Edinburgh Postnatal Depression Scale (EPDS) consists of 10 statements 
about depressive symptoms that are rated from 0 to 3 (Cox et al., 1987). Items include 
statements such as “I have been so unhappy that I have been crying,” and “The thought 
of harming myself has occurred to me.” Responses corresponding to 0 are typically 
“Never” or “Not At All,” and those corresponding to 3 are typically “Most of the time” 
and “Very Often.” Items are summed together to provide a total score, with larger 
scores suggesting greater levels of depressive symptoms. Pregnant women are asked to 
think about how they have felt in the past week, providing a snapshot of mood during 




that the scale’s sensitivity varied from 76-100% and specificity from 70-99% (Gibson et 
al., 2009). The tool is reported to be more sensitive when administered in English. Thus, 
the EPDS is well-validated and has acceptable sensitivity and specificity for our 
population. The EPDS is not unidimensional, exclusively measuring depression, and 
includes several symptoms related to anxiety as well (Brouwers et al., 2001). Both 
anxiety symptoms and depressive symptoms are more accurately measured when using 
the total 10-item EPDS than if divided into separate scales, so total scores on the EPDS 
are also reflective of general anxiety among mothers in the study.  
The Perceived Stress Scale (PSS-14) consists of 14 statements where individuals 
rate perceived levels of stress from general situations over the last month on a 4-point 
scale from 0-“Never” to 4-“Almost Always” (Cohen et al., 1994). Items are summed 
together to produce a total score, with higher scores suggesting higher appraisals of 
stress for different life events. Items include statements such as, “[i]n the last month, 
how often have you felt difficulties were piling up so high that you could not overcome 
them?” Internal consistency across several validity studies was adequate, with a 
Cronbach's alpha >.70, and test-retest reliability for the PSS-14 was similarly >.70 (Lee, 
2012). Hypothesis testing, conducted by Lee (2012), revealed that the PSS was 
moderately-strongly correlated with emotional variables, such as depression or anxiety. 
High scores on the PSS-14 have been correlated with high cortisol in some previous 
studies (Van Eck & Nicolson, 1994). 
The Pregnancy Related Anxieties Questionnaire-Revised (PRAQ-R) consists of 10 




“definitely not true” to 5-“definitely true” (Huizink et al., 2004). Items are summed 
together to produce five subscales and a total score, with higher scores indicating 
higher anxiety. The subscales include the following categories “fear of giving birth,” 
“fear of bearing a handicapped child,” and “worries about changes in appearance.” The 
category, “fear of giving birth,” includes statements such as, “I am worried about the 
pain of contractions and the pain during delivery.” “Fear of bearing a handicapped 
child” includes statements like “I am afraid our baby will be stillborn, or will die during 
or immediately after delivery.” “Worries about changes in appearance” includes 
statements like “I am worried about my enormous weight gain.” The PRAQ-R has good 
reliability and validity (Huizink et al., 2004). The internal consistency was satisfactory, 
with a Cronbach's alpha of 0.79-0.83 for “Fear of giving birth,” 0.87-0.88 for “Fear of 
bearing a physically or mentally handicapped child,” and 0.76-0.83 for “Concern about 
one's appearance.” 
The Psychiatric Epidemiology Research Interview Life Events Scale (PERI LES) is 
a list of 23 events that fall into five domains: relationships, health, legal matter, 
work/finances, and friendships (Dohrenwend et al., 1978). Examples of items include 
events such as “did not get expected wage or salary increase” and “a close friend died.” 
The stressors are categorized as either “good” or “bad” and then summed to derive a 
positive and a negative life event scale. The scale has been validated against reported 
narratives, where raters were asked details of the events (Dohrenwend, 2006). Test-




In addition to these five anxiety measures, mothers also participated in the Mini-
International Neuropsychiatric Interview (MINI) at each annual visit. The MINI is a 
semi-structured diagnostic interview separated into several sections by disorder 
(Sheehan et al., 1998). For each disorder, one or two screening question(s) are asked. If 
positively endorsed, follow-up symptom questions are asked, and if negative on the 
screener question(s), the interviewer moves onto the next disorder section. If a 
diagnostic threshold is reached for a given disorder, questions about chronicity and 
timeframe are then asked. The MINI includes sections pertaining to the top 19 disorders 
in terms of epidemiological prevalence, and includes major depressive disorder, panic 
disorder, social phobia, generalized anxiety disorder, and posttraumatic stress disorder. 
When compared to the SCID-P, the MINI’s sensitivity was 0.70 or higher for all 
disorders except for three (Sheehan et al., 1998). Specificity and negative predictive 
values were at least .85 or greater for all disorders.  
Hair steroid panel. Cortisol and DHEA were measured via the collection of hair 
samples. This method has several advantages over other sampling techniques: hair 
glucocorticoids serve as markers of average stress levels across time. Hormones get 
integrated into hair via circulating blood during the formation of the hair shaft, with 
one centimeter of hair growth reflecting average hormone levels across the previous 
month (Sauve et al., 2007). Logistically, collecting continuous saliva samples over a 
month is not feasible but by collecting hair samples, this technique bypasses that 
limitation. It also enables researchers not to have to consider infants’ circadian rhythm 




Hair was collected and analyzed following the procedure outlined in Sauve et al. 
(2007). In short, during specimen collection, a bundle of approximately 100 hairs was 
cut from the posterior vertex of each infant’s head, as close to the scalp as possible. All 
hair samples were stored in envelopes at room temperature. Samples were sent to 
Kausubaum’s lab in Germany for processing, where a 3-cm section, obtained from the 
scalp end was used for the assays of a full-steroid panel, including cortisol, cortisone, 
DHEA, melatonin, progesterone, and estrogen.  These samples were weighed and 
broken down into small sections in a glass vial. Hormones were extracted via a 16-hour 
incubation in 1 mL of methanol held at 52 degrees Celsius. Following incubation, the 
supernatant was transferred to glass tubes and was exposed to a stream of nitrogen in a 
dry bath until fully evaporated. The samples were subsequently resuspended in 250 mL 
of phosphate buffered saline held at pH 8 and were then vortexed for 1 minute. 
 
Parental Reports of Infant Anxiety. Temperament can be conceptualized as an 
individual’s basic tendency of emotional and attentional reactivity, as well as self-
regulation (Rothbart et al., 2006). “Temperament” is a very early measure of an 
individual’s unique characteristics and may be one of the first ways to conceptualize 
differences in individuals’ reactions to stressors. Temperament arguably emerges as 
early as in the womb and by 6 months-old, the infant is typically displaying a full range 
of approach behaviors and reactions to distress (Rothbart & Bates, 2007). Temperament 
can be measured by the speed and intensity of a behavioral response and the self-




Bates, 2007). Though features of temperament can be categorized in different ways, 
three dimensions have generally emerged in the literature: negative emotionality, 
positive emotionality, and constraint, each relating to different psychopathology to 
varying degrees. Early temperament has been proposed to predict later 
neurobehavioral development, impairment, and disorders. For instance, highly reactive 
temperament, with minimal self-regulatory mechanisms, may predispose children for 
later anxiety disorders (Lonigan et al., 2004).   
 In our sample, these early emotional deviations can be measured via the revised 
Infant Behavior Questionnaire (IBQ-R) Short (Gartstein & Rothbart, 2003). The IBQ-R 
Short includes 91 items in which mothers were asked to report on the relative frequency 
of infant reactions in various situations within the previous week using a 7-point scale. 
The questionnaire generates 14 subscales that fall under 3 categories of negative 
affectivity, surgency/extraversion, and orienting/regulation. Negative affectivity 
includes questions regarding sadness, fearfulness, distress to limitations, and rate of 
recovery from distress. Extraversion includes approach, vocal reactivity, high intensity 
pleasure, smiling/laughter, activity level/energy, and perceptual sensitivity. 
Regulation includes low intensity pleasure, cuddliness, duration of orienting, and 
soothability. This measure shows good reliability, with a chronbach alpha between .70-
.90 for ages 3-9 months old.  
The Behavior Assessment System for Children-2 (BASC-2) was utilized as the 
offspring in the longitudinal study became too old to be administered the IBQ. The 




to the clinical diagnosis of several psychological disorders. It consists of statements 
rated on a 4-point scale from 1-“Never” to 4-“Almost Always” (Kamphaus, 2014). Three 
composite scores are produced, including Externalizing Problems, Internalizing 
Problems, and Adaptive Skills. The Externalizing Problems composite include the 
categories of hyperactivity, aggression, and conduct problems. The Internalizing 
Problems composite include anxiety, depression, and somatization. The School 
Problems composite consists of ratings on learning and attentional problems. The 
Behavioral Symptoms Index (BSI) provides a broad composite of overall problem 
behaviors. The psychometric properties of the BASC-2 are strong, as it is a well-
validated measure that is frequently used in research studies. The parent-report version 
of the questionnaire had test–retest reliabilities in the low .90’s. In the present study, 
BASC questionnaires were given to mothers to fill out at each annual visit, and the 
questionnaire that corresponded to the visit that the hair sample was collected was used 
in the analyses.  
 
Statistical analysis.  
Analyses of variance (ANOVAs) for continuous variables and Chi-square tests 
for categorical variables were utilized in order to assess group differences (Cannabis 
Exposed vs. Control) across demographic, birth and maternal psychological factors. 
Analysis of Covariance (ANCOVAs) utilizing generalized linear model (GLM) 
evaluated the effects of prenatal cannabis exposure on stress hormone concentrations by 




cortisol). All analyses were performed first without potential confounders (Model 1), 
then with potential biological confounders, including a priori determined maternal and 
child demographic confounders and prenatal factors (i.e., gender, substance exposure, 
etc.; Model 2), and, lastly, with the addition of a priori maternal sociodemographic 
factors that differed significantly between the two groups (Model 3). GLM was then 
used to evaluate potential interaction effects between cannabis exposure, and several 
variables of interest, particularly measures of maternal anxiety (i.e., stressful life events, 
trait-anxiety, etc.). SPSS version 19 was used to perform the aforementioned statistical 
procedures.  
Rather than conceptualizing maternal anxiety as five distinct continuous 
variables, distinct categories were created (considered a “latent variable” since the 
category that one falls into cannot be measured directly). The maternal stress and 
anxiety-related questionnaires were useful for categorizing mothers in this study into 
these different categories. Using Mplus version 6, a latent profile analysis (LPA) was 
used to combine measures related to maternal anxiety into a single categorical anxiety 
variable. Mplus estimates the probability that each participant belongs to each of the 
proposed classes and sorts participants into the category with the best fit. The variable 
was then used in the GLM to explore potential interaction effects. This procedure has 
been used in many different fields of psychology (Tein et al., 2013). Missing data were 
negligible (EPDS, 2.3%; PRAQ-R, 3%; PSS-14, 0.7%; STAI, 2.3%; and negative PERI LES, 










Table 1 provides results of comparisons between the prenatal cannabis exposure 
group and controls regarding offspring sociodemographic information and birth 
outcomes, as well as maternal sociodemographic information. Overall, 6.6% of our 
sample was reportedly exposed to cannabis prenatally, which is within the range 
reported in the literature (Young-Wolff et al., 2017). On average across conditions, the 
biological mothers in this study were 27 years old at the time of their child’s birth. There 
were no significant differences in maternal age between unexposed and exposed 
groups, F(1, 230) = .12, p = .73. However, education levels significantly differed; 
mothers in the exposed group had achieved a lower level of education, with 63% of 
mothers in the prenatal cannabis group reporting a high school education or lower, 
versus 32% in the control group, X2 (4, 239) = 11.2, p =.03. Although a large percentage 
of the mothers in each group reported that they were single at the time of their 
pregnancy, marital status differed significantly, with the unexposed group mothers 
reporting higher percentages of married statuses than the exposed group X2 (4, 237) = 
22.12, p <.001. Lastly, levels of maternal anxiety were not significantly different between 
the groups F(1, 174) = .45, p = .51. On average, mothers in the study across both groups 




Demographic characteristics of the offspring also differed between the cannabis-
exposed and unexposed groups. On average across conditions, the age at which the hair 
sample was collected was 2 years 10 months, with a standard deviation of 
approximately one year. However, in the cannabis-exposed group, the infants were 
significantly older, averaging 3 years 7 months when their hair sample was collected, 
while the unexposed group was 2 year 9 months on average F (1 ,239) = 8.41, p = 0.004. 
There were also significant gender differences between the two groups, with a roughly 
even gender split in the unexposed group, but significantly more females in the 
cannabis-exposed group X2 (1, 241) = 3.94, p = .05. The racial composition in each group 
was not significantly different, but there was a higher percentage identifying as African 
American in the cannabis-exposed group than in the unexposed group (44% vs. 17%), 
X2 (4, 239) = 8.04, p =.09. A percentage of each group was exposed to other substances in 
utero, and the ratio of exposed to unexposed differed significantly between the groups 
such that the cannabis group had a significantly higher rate of prenatal tobacco 
exposure (31% vs. 11%), X2 (1, 241) = 5.56, p = .02. The same was true for prenatal 
alcohol exposure (19% vs. 4%), X2 (1, 241) = 7.92, p = .005.  
Although offspring demographic characteristics largely differed between the 
cannabis-exposed and unexposed groups, birth outcomes did not. Unlike predictions 
from the literature where prenatal exposure to other substances of abuse (tobacco, 
alcohol, cocaine, etc.) predict alterations in birthweight, prenatal cannabis exposure was 
not associated with any significant differences in birth measurements. Average 




at approximately 39 weeks F(1,197) = .11, p = .75. Body length was similar between 
groups F(1,158) = .07, p = .80. Birthweight did not differ significantly, but there was a 
trend for the exposed group to be born at a slightly lower birth weight, F(1,213) = 3.41 , 
p = .07.  
 
Prenatal Maternal Anxiety. Latent Profile Analysis 
As stated earlier, the latent profile analysis (LPA) was used to extract anxiety that 
mothers experienced during pregnancy on a latent level, using state anxiety and trait 
anxiety from the STAI, pregnancy-related anxiety, prenatal depression, perinatal PTSD, 
and stressful life events (Cohen et al., 1994; Cox et al., 1987; Dohrenwend et al., 1978; 
Huizink et al., 2004; Spielberger et al., 1983).  LPA procedure resulted in models with 
two, three, and four classes. The three-class model, representing Low, Moderate, and 
High maternal anxiety, best fit the data based on Bayesian Information Criteria 
(Schwarz, 1978), the adjusted BIC (Sclove, 1987), the Lo-Mendell-Rubin test (Lo et a., 
2001), and entropy values (Table 2). The Bayesian Information Criteria (BIC) or Akaike 
Information Criteria (AIC) are two of the most commonly used methods for selecting a 
model that is the most parsimonious or able to explain something with as few predictor 
variables as possible (Tein et al, 2013). For data in this study, both the BIC and AIC 
values continued to decrease (i.e., better fit) from the two-class model to the four-class 
model. The entropy index is another test used to assess parsimony of different latent 
class models and is based on how uncertain an individual’s classification is (Tein et al, 




suggest that the latent classes are highly discriminating between different categories. 
Entropy values in the current sample were acceptable for the two-class, three-class, and 
four-class models. Finally, the Lo-Mendell-Rubin test (L-M-R test) indicated that the 
two-class, three-class, and four-class models all provided good fit. A small probability 
value indicates that a given model provides a significantly better fit for the data than 
the model directly preceding it (Tein et al, 2013). When comparing the model fits, 
between two-class and three-class models, there was a significant improvement 
(p=.0021). Thus, the three-class model was selected, and the mothers were divided into 
low (n = 99, “1”), medium (n = 99, “2”), and high (n = 39, “3”) anxiety groups. Although 
the difference between the three-class and four-class models also demonstrated 
significant improvement, the smaller number of classes was selected to maximize 
parsimony.  
 
Hormone Concentration - Main Effects 
The initial univariate ANOVA revealed that there was a significant difference in 
concentrations of hair cortisol among the cannabis-exposed and unexposed groups 
(Model 1). On average, infants prenatally exposed to cannabis demonstrated 
significantly higher concentrations of cortisol than the unexposed infants F (1, 176) = 
11.82, p < .001; n2 = .06. Fig. 1 illustrates the average hair cortisol concentrations of 
infants prenatally exposed to cannabis compared to the average of unexposed controls. 
When covarying for biological factors in Model 2, including infant age, gender, prenatal 




unchanged, F (1, 177) = 10.68 p = .001; np2 = .06. Prenatal tobacco exposure alone was 
not significantly associated with differences in cortisol levels, F (1,176) = .96, p = .33, np2 
= .01, nor was prenatal alcohol exposure, F (1, 176) = .36, p = .55, np2 = .002. However, 
child’s sex was significantly associated with cortisol concentrations within this model, F 
(1,177) = 4.62, p = .03, np2 = .03. Female infants had a higher average concentration of 
cortisol than male infants. When adding maternal sociodemographic variables to the 
model that were significantly different between the two groups, which included marital 
status and maternal education (Model 3), the main effect of prenatal cannabis exposure 
remained significant, F (1,174) = 5.93, p =.02, np2 = .04.  
With regard to other stress hormone concentrations, univariate ANOVA 
revealed that there was a significant difference in concentrations of hair DHEA among 
the cannabis-exposed and unexposed groups (Model 1). On average, infants prenatally 
exposed to cannabis demonstrated significantly higher concentrations of DHEA than 
the unexposed infants F (1, 223) = 6.07, p = .02, n2 = .02. Fig. 1 illustrates the hair cortisol 
concentrations of infants prenatally exposed to cannabis and of unexposed controls. 
Initial unadjusted model (Model 1) was followed by adjusted model with covariate 
using univariate ANCOVA (Model 2) with additional biological factors, including 
infant age, gender, prenatal alcohol exposure, and prenatal tobacco exposure., These 
results were largely unchanged, F (1, 224) = 5.57 p = .02; np2 = .03. Similar to cortisol 
levels, prenatal tobacco exposure alone was not significantly associated with differences 
in DHEA levels, F (1, 224) = .01, p = .93, np2 < .01, nor was prenatal alcohol exposure, F 




variables to the model (Model 3), which included marital status and maternal 
education, the main effect of prenatal cannabis exposure itself was no longer significant, 
F (1,224) = .65, p =.42, np2 < .01.  
 
Hormone Concentration – Interaction Terms  
As mentioned previously, cannabis exposure was associated with higher levels 
of infant cortisol, but significant 2-way interactions emerged with both age and 
birthweight (Table 3). Age and cortisol concentrations were not significantly correlated 
(r = -0.07, p = 0.39), but further analysis revealed a significant interaction between 
prenatal cannabis exposure and age (F = 4.587, p = 0.01; Cohen’s d = 0.77). For offspring 
not exposed to cannabis prenatally, average cortisol concentrations were highest at 
younger ages and decreased to a lower concentration among the older ages (Table 3). 
Among the cannabis-exposed infants, this relationship was reversed; as age increased, 
average cortisol concentrations were higher. Similarly, although birthweight and 
cortisol concentration were not significantly correlated (r = -0.06, p = 0.48), a significant 
interaction emerged between cannabis exposure and birthweight (F = 4.96, p = <0.01; 
Cohen’s d = 0.80). For cannabis-exposed infants, as birthweight decreased, cortisol 
concentrations generally increased, whereas for unexposed infants, their cortisol levels 
did not vary predictably with birthweight. 
Prenatal cannabis exposure was also associated with higher levels of DHEA in 
exposed infants, and like cortisol, significant interactions emerged for birthweight and 




DHEA concentration, (r = -0.11, p = 0.11), but a significant interaction emerged between 
cannabis exposure and birthweight, F = 4.33, p = 0.02; Cohen’s d = 0.75. When exposed 
to cannabis in utero, birthweight had a differential impact on DHEA levels that was 
similar to cortisol, with lower birthweight associated with higher DHEA levels, and no 
relationship for the unexposed group. Analyses also revealed a significant interaction 
between infant age and prenatal cannabis exposure (F = 3.22, p= 0.04, Cohen’s d = 0.61). 
Despite DHEA demonstrating no significant correlation with infant age overall (r = .04, 
p = .55), prenatal cannabis exposure appeared to be associated with higher DHEA levels 
when an infant was older.  
A small number of mothers in the current study reported alcohol and/or tobacco 
use during pregnancy. Alcohol use, alone, was not significantly associated with cortisol 
levels, F(1,176) = .08, p = 0.78, or concentrations of DHEA F (1, 223) = .35, p = .55. 
Similarly, tobacco use, alone, was not significantly associated with cortisol levels, F 
(1,176) = .08, p = 0.78, or concentrations of DHEA, F (1, 223) = .35, p = .55.  Prenatal 
tobacco and alcohol use were combined into one variable representing either substance 
exposure for further interaction analyses.   
In addition to prenatal substance use, the potential influence of maternal anxiety 
on offspring stress hormone concentrations was assessed. Scores from several 
questionnaires were amalgamated into one maternal anxiety factor through an LPA as 
previously discussed. This amalgamated variable of maternal anxiety was not 
significantly associated with DHEA, F (1,195) = .23, p = 63. However, specific to DHEA 




anxiety measure and cannabis exposure F(1,195) = 3.47, p = 0.03. Without prenatal 
cannabis exposure, maternal anxiety does not appear to affect a child's DHEA levels, 
but when there was cannabis exposure, increased maternal anxiety is associated with 
higher concentrations of DHEA in offspring. The amalgamated maternal anxiety 
measure was not significantly associated with infant cortisol levels, F (1,151) = .03, p = 
.88, and the interaction with prenatal cannabis was not significant F (1,151) = 1.64, p = 
.20.  
A significant 3-way interaction emerged between prenatal cannabis, other 
prenatal substance exposure, and maternal prenatal anxiety F (1,151) = 5.22, p <0.01, 
Cohen’s d = 0.83. In offspring without prenatal cannabis exposure, maternal anxiety 
had no discernable effect on DHEA levels, whereas alcohol and tobacco generally 
lowered levels. In infants with prenatal cannabis exposure, higher maternal anxiety and 
in utero polysubstance exposure in combination are associated with higher levels of 
DHEA. A significant 3-way interaction also emerged between prenatal cannabis, other 
prenatal substance exposure, and infant age F (1,151) = 5.22, p = 0.03, Cohen’s d = 0.66. 
With no cannabis exposure, age is associated with a slight increase in DHEA 
concentration seen over the cross-section of children, and children with tobacco 
exposure and/or alcohol exposure appear to generally have lower levels of DHEA. 
However, within the cannabis exposure group, the increase in DHEA concentrations is 
even steeper, especially in polysubstance exposed children.  
Lastly, combining the influence of several factors, the data supported a 




exposure to tobacco and/or alcohol, and maternal anxiety for DHEA concentrations, F 
= 3.51, p = 0.03, Cohen’s d = 0.65. At younger ages, the influence of cannabis, other 
substances, and maternal anxiety is not as apparent (and, in some cases, it's reversed). 
As age increased in the cannabis exposed sample, the additive risks became more 
apparent. When the child had been exposed prenatally to cannabis, tobacco and/or 
alcohol, and higher maternal stress, the combination of these factors was associated 
with higher DHEA levels in infancy, especially at older ages. 
 
Child Anxiety Outcomes 
Controlling for maternal trait anxiety, maternal report of early infant fearfulness 
demonstrated significant group differences based on prenatal substance exposure. On 
average, infants exposed to cannabis had significantly higher reported fearfulness, 
F(1,92)= 7.75, p = .007. Tobacco-exposed infants also had higher reported fearfulness, 
F(1,92) = 6.76, p = .01, and a significant interaction emerged, where polysubstance 
exposure resulted in significantly higher levels of fearfulness than either substance 
alone, F(1,92) = 4.87, p = .04. Prenatal alcohol exposure also significantly interacted with 
cannabis exposure, but in this combination, infants exposed to both substances 
prenatally had the lowest average reported fearfulness scores, and those with just 
cannabis exposure had the highest F(1,92) = 8.00, p = .006.  
The BASC-2 was used to measure child anxiety at the time of stress hormone 
collection. For both DHEA and cortisol, higher reported anxiety in the offspring was 




.67, p < .01; r= .63, p = .03. However, there were no significant group differences in the 
anxiety scores reported for prenatally-exposed offspring around the time that their hair 
samples were collected.  Exploratory analysis within just the cannabis-exposed group 
revealed a significant correlation between concentrations of cortisol and the child’s 
reported anxiety levels, r = .63, p = .03. The same relationship was evident for anxiety 
and DHEA concentrations, r = .69, p = .005. Overall, higher levels of biological stress 
hormones were significantly associated with higher levels of reported anxiety for the 


































Consistent with previous literature, our findings provide biological evidence in 
support of emotional dysregulation in substance-exposed offspring, specifically for 
prenatal cannabis exposure. The current study confirmed the findings of the recently 
published Cajachagua-Torres et al. (2021) study that prenatal cannabis exposure was 
associated with higher cortisol concentrations in exposed children. The study 
specifically used the same specimen collection techniques, by analyzing hair samples 
for aggregate hormone concentrations, rather than focusing on diurnal patterns or acute 
responses to a stressor. Additionally, the children in the aforementioned study were 
approximately six years-old, whereas the children in the current study were on average 
two years and ten months old. Thus, the results of both studies, in combination, 
demonstrate continuity between infancy and early childhood in the reported elevated 
levels of stress hormones in offspring. The current study additionally expanded 
analyses to include an investigation of DHEA concentrations, which were also found to 
be elevated in the prenatally exposed group. To our knowledge, this is the first study to 
assess DHEA at such an early timepoint and to arrive at important conclusions about 
differences in children who have been prenatally exposed to cannabis.  
Based on the previous literature review, several biological mechanisms have 
been elucidated, which can explain how prenatal cannabis exposure can lead to the 




cannabinoid receptors during critical periods of fetal maturation may significantly 
disrupt typical developmental pathways. THC exposure can disrupt endocannabinoid 
signaling and can rewire synapse formation during early fetal development. 
Similar to previous studies, early differences in temperament specific to elevated 
fearfulness were found in substance-exposed infants. By early childhood, maternal 
reports of their child’s anxiety did not differ significantly between the groups, which 
was contrary to our originally stated hypothesis. However, specific to the cannabis-
exposed group only, the child’s reported anxiety levels correlated with concentrations 
of cortisol and DHEA. There was a high degree of heterogeneity in the exposed group 
that could account for some of these non-significant between-group comparisons.  
Overall, the present study did not just confirm the findings of previous research 
studies, but it extended them to include explanations of how maternal anxiety, 
birthweight, and other prenatal substance exposures can interact with prenatal cannabis 
exposure to produce higher concentrations of stress hormones. Each of these variables 
carry their own set of risks for aberrant neurodevelopment in offspring that may 
compound issues related to cannabis exposure alone.  
There is growing evidence that heritability plays a crucial role in explaining 
variation in anxiety among children. Early studies found that mothers of children with 
overanxious disorder (OAD) had increased prevalence of OAD, themselves (Last et al., 
1987). Follow-up studies confirmed greater rates of current and lifetime anxiety 
disorders in mothers of anxious children (Cooper et al., 2006). Anxious children tend to 




correlated between mother and child dyads (Creswell et al., 2005). Maternal anxiety 
during pregnancy can transfer maternal cortisol across the placenta to the fetus, and this 
increased fetal exposure to cortisol in utero may mediate the relationship between 
prenatal maternal anxiety and altered emotional outcomes in offspring (Glover, 2014). 
The 11B-HSD2 gene encodes proteins that catalyze conversion of cortisol to inactive 
cortisone, and prenatal stress has been shown to reduce placental 11B-HSD2, 
demonstrating one possible biological mechanism for this transfer for risk from mother 
to offspring (Glover, 2014). Infants born with low birth weight often display many of 
these same characteristics, including higher levels of reported negative emotionality 
(Blair, 2002).  
Prenatal alcohol exposure bears its own set of risks for negatively impacting 
offspring stress response. Prenatal alcohol exposure is associated with higher baseline 
and post-stress cortisol reactivity/concentrations in exposed infants (Hellemans et al., 
2010).  In the animal models reviewed by Hellemans and colleagues, prenatally-exposed 
mice demonstrate clear signs of anxiety by spending less time in the open arms of a 
maze. In human studies, fetal alcohol syndrome disorders are commonly associated 
with depression and anxiety disorders in both children and adults. Similarly, prenatal 
tobacco exposure has also been associated with negative emotionality, characterized by 
heightened anxiety, mood disorders, and internalizing behaviors (Carter et al., 2008; 
Eppolito et al., 2010; Indredavik et al., 2007; Moylan et al., 2015; Schuetze & Eiden, 
2007). Schuetze and Eiden (2007) identified increased negative affect in tobacco-exposed 




primary target of nicotine, may affect the development of key limbic circuitry, 
particularly during puberty in adolescence (Dwyer et al., 2009). However, less is known 
about tobacco’s immediate effects on the infant limbic system and the expression of 
negative emotionality. In the Cajachagua-Torres et. al (2021) study, prenatal tobacco 
use, by itself, was not associated with deviations in cortisol levels in early childhood, 
which was similar to the result obtained in the current study. However, polysubstance 
exposure appeared to affect stress hormone levels in exposed infants when combined 
with other risk factors.  
In utero exposure to tobacco and/or alcohol carry their own set of risks and can 
exacerbate the proposed risks associated with cannabis use alone. In fact, several drugs 
of abuse appear to share the same negative disruptive influence on key, interconnected 
dopaminergic brain regions like the prefrontal cortex, which is intimately connected to 
the HPA axis (Derauf et al., 2009). In this previous neuroimaging review study of 
prenatal substance exposure, proposed compensatory mechanisms capitalize on the 
brain’s neuroplasticity and highlights the ability of the brain to recover from early 
disruption in development. For example, the review paper highlights a study by Rao et 
al. where imaging of adolescents who had prenatal cocaine exposure demonstrated 
increased cerebral blood flow in select brain regions thought to compensate for reduced 
global blood flow experienced during early neural development. In another study cited 
by these authors, adolescents with prenatal cannabis exposure displayed similar 
performance on an inhibition task as unexposed controls, but recruited higher 




the brain’s efforts at neuronally reorganizing in order to compensate for early 
developmental disruption. However, polysubstance exposure, in combination with 
other risk factors like maternal anxiety, may potentially override the brain’s early efforts 
at compensating, and the early exposure may lead to noticeable functional weaknesses 
and measurable alterations in glucocorticoid levels. 
The allostatic load hypothesis proposed by McEwen (2003) posits that successive 
stressors and risk factors can lead to “wear and tear” on the body and brain, which 
leaves an individual more susceptible to later insults. In applying this theoretical 
framework, we begin to understand how prenatal exposure to multiple types of risk 
factors can leave offspring vulnerable to adverse postnatal outcomes. For example, 
exposed offspring born at lower birthweight and to mothers experiencing high stress 
and anxiety throughout their pregnancy (demonstrating cumulative risk) had higher 
cortisol concentrations at older ages. This early “wear and tear” related to multiple risk 
factors likely leaves infants and children vulnerable to later environmental insults, such 
as suboptimal parenting or a stressful home environment.  
Specific to emotional development, early risk factors and additional insults to the 
stress-response system can impact the development of an anxiety disorder later in life. 
The Developmental Origins of Health and Disease theory hypothesizes that events in 
utero may influence the occurrence of several health concerns and neuropsychiatric 
disorders later in development (Gillman, 2006). More specifically, the Adaptive 
Calibration Model of stress responsivity posits that an infant’s inborn HPA axis (stress 




experiences (Del Giudice et al., 2011). The model defines stress responsiveness styles by 
integrating several risk factors, like anxiety, environmental stressors, and individual 
responsiveness to stress, that start to interact during the prenatal period and influence 
outcome across the lifetime. 
In the present study, although some offspring in the exposed group seemed to be 
negatively impacted by the additive prenatal risk factors, others were not. Paradoxical 
findings regarding cannabis’ status as anxiolytic verses anxiogenic may explain our 
sample’s fairly large within-group variability. Manipulation of dose and timing of 
cannabis exposure may be associated with contrary results, either increasing or 
decreasing anxious behaviors in exposed offspring. For instance, in an experiment in 
which a cannabinoid agonist was injected directly into the prefrontal cortex of rats, an 
anxiolytic effect resulted from moderate doses and an anxiogenic effect from larger 
doses (Rubino et al., 2007). Therefore, the large group variability of our sample may be 
explained by the opposing effects of cannabis that result from variations in timing and 
intensity of the prenatal exposure.  
Generally, effects of prenatal cannabis are difficult to ascertain, given that these 
opposing effects would negate any meaningful group differences, and therefore two 
offspring grouped together in the same “exposed” category may have opposite 
neurobehavioral outcomes. Indeed, conflicting behavioral results have been found in 
human studies. In a study by Fried and Makin (1987), exposed newborns demonstrated 
poorer habituation, higher irritability and increased tremors/startles. However, the 




cannabis-exposed newborns actually demonstrated better physiological stability. 
Therefore, we are cautious to apply our findings to all cannabis-exposed offspring, and, 
instead, want to highlight the differential impact of cannabis exposure, which likely 
negatively impacts some, but not all, offspring. Future studies are thus critical in order 
to elucidate differences in vulnerability to the various risk factors and to delineate the 
relationship between dose/frequency and negative outcomes.  
To illustrate the aforementioned variability in presentation and outcome, three 
mother-infant dyads within the cannabis-exposed group are highlighted and discussed 
in detail below.  
 
Case 1: Mother A in the cannabis group is a single, high school educated African 
American female. During the pregnancy of her fourth child, she reported smoking 
cannabis daily but did not use cigarettes or other drugs. Her questionnaires indicated 
low levels of maternal anxiety and stress during her pregnancy, and she had no 
psychiatric history. Her infant daughter was born healthy and full-term, and her 
birthweight was within normal limits. She reported that her child had moderate levels 
of fearfulness in infancy at 6 months-old. By middle childhood, the child’s reported 
anxiety went from the average range to clinically significant levels (96th percentile) on 
the BASC questionnaire. Hormone assay during that time revealed a high concentration 
of cortisol and high levels of DHEA. Overall, the child had minimal risk factors from 
pregnancy, besides the daily cannabis exposure, and maternal anxiety was low. 




exposure, and corresponding behavioral difficulties became more apparent later in 
childhood.  
 
Case 2: Mother B in the cannabis exposure group was a single high school 
educated Caucasian female who similarly used cannabis during her pregnancy, but she 
did not use cigarettes or other drugs. Unlike the previous mother, this participant was 
homeless prior to her pregnancy. Psychiatric history was significant for bipolar 
disorder, and she also underwent outpatient treatment for a marijuana use disorder. 
Despite these heightened risk factors, during the pregnancy of her seventh child, she 
reported low maternal anxiety and stress. Her daughter was born full-term, with a 
birthweight in the 97th percentile. She had low reported fearfulness in infancy and low 
anxiety in childhood that corresponded to low concentrations of cortisol and DHEA. It 
is clear that the association between prenatal cannabis exposure and heightened 
anxiety/stress hormone concentrations is not absolute for all exposed offspring. Timing 
of exposure and genetic variation likely account for differences in outcome. However, 
the scope of this study was restricted to early development, and thus may miss the 
longitudinal aspect of possible emerging anxiety difficulties later in life related to 
prenatal exposure.  
 
Case 3: Mother C is a single, high school educated Hispanic female. She was in 
treatment for a cannabis marijuana use disorder and also endorsed smoking cigarettes 




with major depressive disorder, social phobia, generalized anxiety disorder, and 
antisocial personality disorder. During her fourth pregnancy, she reported high stress 
and anxiety levels. Her daughter was born preterm at 35 weeks, with low birthweight 
overall, and low birthweight for gestational age. The mother reported high infant 
fearfulness at 1 year-old, and later anxiety levels in the 92nd percentile when the child 
was 3 years-old. The concentrations of both cortisol and DHEA were similarly high at 3 
years-old. Given that there were many risk factors known to be associated with high 
stress hormones and anxiety, it is difficult to tease apart separate contributions, but 
additive risk appears likely. This final example of an infant-mother dyad in the 
cannabis-exposure group lends support to the idea of additive risk. 
Several aspects of the postnatal environment may also be impacting 
concentrations of stress hormones in offspring. Particularly in GLM model 3, the 
addition of sociodemographic factors to the model (i.e. maternal education and marital 
status) reduced the impact of prenatal cannabis exposure in explaining DHEA 
concentrations in infants. Previous research has demonstrated that factors like family 
income, parental education and marital status, can significantly impact concentrations 
of stress hormones on offspring (Bates, 2017; Hagaman et al., 2020; Rippe et al. 2016; 
Tomasi & Volkow, 2021; Ursache et al., 2017; Vliegenthart et al., 2016). In a very large 
sample of 10-year-olds, family income and offspring DHEA concentrations were found 
to have a significant negative correlation; lower income was associated with higher 
levels of DHEA in these children (Tomasi & Volkow, 2021). However, in another study 




found to have a significant positive association with infant DHEA levels (Hagaman et 
al., 2020). It is therefore possible that family socioeconomic factors exert differential 
effects on offspring, depending on the age of the child, and that this association can 
explain the impact of sociodemographic factors found in the present study. A low 
household socioeconomic status (SES) may predict lower concentrations of DHEA in 
offspring at very young ages, but an increase in DHEA over time may be the body’s 
way of combatting harmful effects of stress brought on by the external environment. 
The present study may have been able to capture the approximate age at which this 
shift in DHEA concentrations occurs in response to constant post-natal environmental 
stress.  
Aside from differences in DHEA concentrations, family income, parental 
education and marital status was also associated with higher hair cortisol levels in 
children ranging in age from 1-7 years old (Bates, 2017; Rippe et al. 2016; Ursache et al., 
2017). Specifically, lower income, lower maternal education and a single marital status 
were correlated with higher levels of cortisol in these offspring. This relationship was 
similarly found in older children/adolescents as well (Vliegenthart et al., 2016). In 
addition to income, marital status and education, factors like racial discrimination, 
which disproportionately affects ethnic minorities, also has the potential to dysregulate 
the HPA axis and disrupt the production of cortisol and DHEA. Indeed, in a study of 
African American emerging adults, higher levels of racial discrimination were 
associated with heightened depressive symptoms, which in turn were associated with a 




younger than the Lee et al. (2021) study, the early impact of racial discrimination may 
already be exerting effects on a child’s HPA axis in ways that have not yet been 
investigated at such an early age, and would be important to investigate in future 
studies.  
It is clear from the current study and other previous research that prenatal 
factors, such as in-utero substance exposure, as well as postnatal factors, like low SES, 
are significantly associated with differences in an offspring’s HPA axis. Cortisol 
concentrations may initially be higher in young children due to exposure to chronic 
environmental stressors. However, after constant exposure to stress, cortisol may 
eventually be downregulated over time and DHEA may be upregulated in order to 
combat the harmful influence of the increased cortisol (Kamin & Kertes, 2017). The age 
at which these stress hormones are measured may therefore dramatically change the 
direction of the results and can explain any conflicting reports in the literature. 
 Jansen et al. (2010) posed a theory for typically observed declines in cortisol 
reactivity across infancy. As an infant expands their knowledge of ways to handle the 
discomfort of a stressor (e.g. crying), the stressor, itself, becomes less potent and thus 
less able to incite a spike in cortisol. The HPA axis, itself, would not necessarily be 
hyporeactive at older ages, but the infant likely becomes better adept at regulating 
responses to stressors. There is a lag between onset of a stressor and peak cortisol levels, 
thus, a regulating behavior could lessen the magnitude of the HPA axis’s response. 
However, individual differences in this are apparent and can be related back to 




demonstrated that at 18 months-old, on a group-level, infants put in a strange 
environment did not generally experience a change in their cortisol levels, but those 
who were in the paradigm and were characterized as generally fearful at baseline and 
insecurely attached, generated heightened cortisol reactivity. This finding showcases 
inter-individual variability and relates to the present study’s attempts at elucidating 
potential risks that may make offspring more vulnerable to a heightened stress 
response.  
Study Strengths 
The current study has several methodological strengths. Although there are 
alternative mechanisms that may explain the observed hormone deviations, without 
involving the direct effects of the prenatal cannabis exposure, our study tried to limit 
contributions from these alternative sources. For instance, maternal trait anxiety may 
independently affect the offspring’s developing stress response system. Given that we 
collected information regarding maternal trait anxiety, analysis revealed that the 
unexposed group was well-matched to the cannabis-exposed groups and, therefore, the 
contribution of the mother’s own stress reactivity to that of her child’s developing stress 
hormone system did not vary considerably between groups. Additionally, features like 
low birth weight, which have been associated with cannabis exposure in some previous 
studies, has been postulated to be one of the mechanisms that underly previously 
reported disturbances in infant affect (Howard et al., 2019; Minnes et al., 2011). 
However, in the current study, birthweight did not significantly differ between groups, 




deviations in birth outcomes. The similarity in birth outcomes between our groups is 
consistent with other studies that have found no association between prenatal cannabis 
exposure and lower birth weight (Mark et al., 2016). 
With regard to collection methods, ascertaining hormone levels from hair 
samples has several advantages over other sampling techniques. Hair cortisol serves as 
a marker of average stress levels across time. Stress hormones are integrated into hair 
follicles via circulating blood during the formation of the hair shaft, with one centimeter 
of hair growth reflecting average hormone levels across the previous month (Sauve et 
al., 2007). Therefore, although collecting continuous saliva samples over a month was 
not logistically feasible in the current study, the sampling method chosen bypassed this 
limitation. It also bypassed consideration of infants’ circadian rhythm when selecting 
the hair collection time.  
Additionally, a notable strength of the current study was the ability to collect 
information about both cortisol and DHEA within the same child. These measurements 
are often investigated in conjunction with each other, with a higher ratio of cortisol to 
DHEA typically representing higher levels HPA axis dysfunction. When concentrations 
of cortisol greatly exceed concentrations of DHEA, it is hypothesized that DHEA is 
unable to counter the harmful impact of cortisol within the human body. In the present 
study, given that both cortisol and DHEA were high in the cannabis-exposed group, the 
ratio may not be as useful in detecting differences between groups in the very early age 
groups. However, as age increases, the difference in concentrations between the two 




represent age-related changes. Future studies should capitalize on the present 
methodology, collecting information on not just cortisol but DHEA as well.  
 
Study Limitations 
Despite the aforementioned strengths, there are important limitations with this 
study, some of which are common to substance-use research in general. As previously 
mentioned, pregnant women who use cannabis often drink alcohol, use cigarettes and 
sometimes use other illicit drugs concurrently. Similar to most studies on prenatal 
substance use, several mothers in the current study did not report solely using cannabis 
during their pregnancy, making it difficult to isolate the potential effects of cannabis 
alone. However, the polysubstance use in our sample may make the findings more 
generalizable to the general population, since co-use naturally occurs quite often. 
However, to address some of these concerns, participants who reported prenatal 
cocaine use were eliminated from the analyses and alcohol/tobacco exposure was 
covaried for between groups. 
Related to substance use, it is not uncommon for women, especially during 
pregnancy, to underreport use, and since exposure status was established based on self-
disclosure and social work records, it is possible that some participants classified as 
unexposed, may have been exposed. Although not feasible in the current study, 
collecting meconium at birth or administering periodic drug testing of all participants 
throughout pregnancy would provide additional evidence for group classifications 




whenever possible. In addition to prenatal variables, adverse parenting can contribute 
negatively to offspring development. An assessment of caretaking skills during the 
infant period, particular for behaviors like soothing, would provide much needed 
information and strengthen current and future findings. 
Methodologically, the steroid panel assay returned several values that were 
above acceptable biological levels and were excluded from the current analysis, 
resulting in the loss of data points. Additionally, the relatively small sample size of the 
substance-exposed groups did not provide us with optimal statistical power and may 
influence the stability of the findings. Larger sample sizes will allow a confirmation of 
these results and the ability to analyze other variables of interest, such as gender 
differences and timing of exposure during the pregnancy, which we were unable to 
assess in the current analysis. However, despite the small sample size, as previously 
mentioned, the current study confirmed the findings of the recently published 
Cajachagua-Torres et al. study (2021) and extended them to a younger age group.  
Lastly, although the current method used to assess stress hormones via hair 
samples was listed as a strength of the study design, one limitation is that this method 
makes it difficult to compare findings with other studies that assessed salivary cortisol 
and DHEA. This study cannot make claims about an individual child’s cortisol 
awakening response or hormonal response to an acute stressor but, rather, can only 
draw conclusions about the overall levels of these hormones, which reflect the child’s 





Other considerations and future directions 
Cannabidiol, known as CBD, is another major cannabinoid isolated from the 
cannabis plant, but it is not known to affect the central nervous system the way that 
THC does and has a different receptor binding affinity (Mechoulem & Parker, 2013; 
Sarrafpour et al., 2020). In fact, it appears to reverse some of the negative impact of THC 
on memory and have therapeutic effects such as anti-inflammatory and analgesic 
properties (Sarrafpour et al., 2020). Particularly during pregnancy, CBD is commonly 
being used to help against vomiting and nausea, as well as to treat anxiety and chronic 
pain. Although presumed to be benign, the current study did not address CBD use 
specifically. Future studies should address the influence of this cannabinoid in order to 
provide much needed literature on safety during pregnancy.  
Aside from the effects of in utero cannabis exposure, during the perinatal period, 
breast milk is also a mechanism that may expose newborns to cannabis. THC is 
detectable in breast milk for up to 6 days after use, and mothers who use cannabis more 
frequently each day have higher concentrations of THC in their breast milk (Bertrand et 
al., 2018). In heavy users, breast milk concentrations of THC can be up to 8x higher than 
concentrations of THC found in blood plasma. Additionally, per Bertrand and 
colleagues (2018), THC can actually reduce the amount and quality of breast milk 
produced.  
THC can thus be found in breast milk that is ingested by newborns. How much 
active THC is transferred to newborns appears low compared to adult doses. Estimates 




lower than concentrations in the blood plasma of an active adult user (ElSohly et al. 
2016). However, despite this finding and, of concern, in one reported case study, a high 
concentration of THC was found in the feces of a newborn nursing from a mother who 
was actively using cannabis. This indicated that the newborn absorbed and metabolized 
cannabis metabolites even though there was a low level of THC present in the breast 
milk. THC concentrations can vary greatly, and it is unknown if exposure to low levels 
of THC postnatally can negatively alter infant development.  
Although the current study did not assess cannabis use by mothers directly 
during the prime breastfeeding years, mothers reported on their use when the child was 
between 2-6 years-old. Many mothers in the prenatal cannabis group reported 
subsequent use during this time period. Therefore, it is likely that some of the mothers 
in the study were using cannabis while breastfeeding and may have transferred any 
risk related to exposure in this manner. To date, there are no published studies in 
humans assessing risks associated with cannabis exposure only during lactation and not 
the pregnancy, given that it would be uncommon for a mother to not use cannabis 
during her pregnancy, but begin using while breast-feeding. Future studies will want to 
carefully assess perinatal cannabis use and potential for exposure.  
Aside from the influence of CBD and possible delivery of THC through breast 
milk, the concentration of THC in various cannabis strains is another important 
consideration in substance use research. Although it is not typically feasible in human 
studies to measure cannabis potency, this is an important consideration for future 




increased over the past several decades. THC content in cannabis in the 1960’s was 
about 2-3%, but modern strains have been developed that contain concentrations of 
THC up to 25% (Mechoulem et al., 2013). If mothers could bring a sample of the 
particular strain that they typically smoke, researchers would be able to naturistically 
assess typical potency. Particularly as legal dispensaries formally catalogue THC 
concentrations, participants may be able to more accurately report on levels of THC in 
the strains that they consume.  
Lastly, in addition to considering the influence of CBD, breastfeeding, and 
cannabis strain potency, future studies assessing prenatal exposure’s impact on the 
endocannabinoid system and HPA axis could benefit from including a measure of 
offspring endocannabinoid concentrations via saliva, hair, or blood. This additional 
measurement would help researchers better understand changes to the underlying 




The current study provides initial evidence that exposure to cannabis in utero is 
associated with early deviations in stress hormone concentrations. Prenatal exposure to 
cannabis and the concurrent alterations in hormone levels may predict an increase in 
early traits like reactivity in infancy. At chronically high levels, cortisol and DHEA can 
lose their ability to inhibit an active HPA axis resulting in a chronically active stress 




concentrations, but higher concentrations may be ineffective or even neurotoxic (Van 
Voorhees et al., 2014; Lennartsson et al., 2012). An inappropriately heightened stress 
response translates into a difficult infant temperament, and a difficult infant 
temperament, especially in the context of poor parenting, may further lead to behavior 
problems and diagnosed psychopathology later in childhood and adolescence (Lester et 
al., 2009). Therefore, these potential alterations in neurobiological mechanisms 
occurring during prenatal development may cause lasting biological changes that 
enhance susceptibility to mood and anxiety disorders later in life (Morris et al. 2011). 
Given the increasingly favorable public opinion towards cannabis and the 
changing legislation around its legal status, replication of the current findings is critical 
in order to inform public health practices surrounding pregnant women and their 
children. If a mother chooses to use cannabis during her pregnancy, it should be of 
utmost importance for her to reduce her own stress and anxiety levels so as not to 
potentially transfer risk to her fetus. However, heightened stress and anxiety may, in 
part, be reasons individuals choose to use cannabis to begin with. Additionally, 
healthier birth outcomes were associated with cortisol and DHEA levels that more 
closely mirrored the levels seen in unexposed children. It is therefore integral for 
mothers who use cannabis during their pregnancy to receive proper prenatal care and 
to mitigate other risk factors that could lead to compromised birth outcomes like early 
delivery or low birthweight. Smoking tobacco during pregnancy has several 
documented risks, but one of the most well-established findings is the association 




Abstaining from tobacco use during pregnancy is well-advised, particularly if a mother 
continues to smoke cannabis, as there appears to be added risk from polysubstance use. 
The same is true for prenatal alcohol use. 
Children born with prenatal cannabis exposure may be at an increased likelihood 
of HPA axis dysregulation, and thus early attempts at teaching emotion self-regulation 
techniques should be emphasized as a preventative measure. Effective coping strategies 
and support from others are likely able to attenuate elevations in children’s overall 
stress hormone levels (Nachmias et al., 1996). This assistance is of particular importance 
to young infants and offspring who already demonstrate signs of fearfulness and 













Table 1. Demographic information by exposure group *p ≤ 0.05 





 (N= 225) 
Cannabis  
(N= 16) P-value 
Age at hair collection (mos.), mean (SD) 33.50 (12.60) 43.12 (15.93) 0.004* 
Gender  
Male, N (%) 







Caucasian, N (%) 
African American, N (%) 
Hispanic, N (%) 
Asian, N (%) 
Other, N (%) 
  44 (20%) 
  38 (17%) 
117 (52%) 
  14 (6%) 







Birth Weight (kg) 3.30 (0.57) 3.02 (0.69) 0.07 
Gestational Age (weeks), mean (SD) 38.88 (2.15) 38.70 (2.13) 0.75 
Body Length (cm), mean (SD) 50.12 (4.37) 50.41 (4.07) 0.80 
Alcohol Exposure N (%) 8 (4%) 3 (19%) 0.005* 
Tobacco Exposure N (%) 25 (11%) 5 (31%) 0.02* 
Maternal Characteristics 
Unexposed 
 (N= 222) 
Cannabis  
(N= 16) P-value 
Age at birth of child (years), mean (SD) 27.41 (6.09) 26.87 (4.96) 0.73 
Education  
      Primary, N (%) 
Some H.S.  N (%) 
H.S. N (%) 
Some College N (%) 
Associates N (%) 
Bachelors N (%) 
Graduate N (%) 
  5 (2%) 
27 (12%) 







8 (50%)  
1 (6%) 
3 (19%)  




Marital Status  
Married, N (%) 
Common Law, N (%) 
Single, N (%) 
Widowed, N (%) 





  0 (0%) 













Figure 1   Mean (± SD) hair cortisol concentrations and mean (± SD) hair DHEA 


















































































Table 2. Fit Statistics for Latent Classes Determining Normative Maternal Anxiety  
Class solution BIC ABIC L-M-R p value Entropy 
 23466.62 23412.57   
2 Classes 22481 21 22395.63 <0.0001  .0.840 
3 Classes 22219.48 22102.37 0.002 .0.805 
4 Classes 22123.27 21974.63 0.007 .0.808 
5 Classes 22086.37 21906.19 .469 .0.811 
Note: BIC, Bayesian Information Criterion. ABIC, adjusted BIC. L-M-R, Lo-Mendell-




































Table 3. Interaction effects between cannabis and other variables of interest on 
DHEA concentrations 
 
DHEA Interaction Terms F p-val power 
  Cannabis x Maternal Anxiety 3.467 0.033* 0.643 
  Cannabis x Infant Age 3.215 0.042* 0.608 
  Cannabis x Birthweight 4.332 0.015* 0.746 
  Cannabis x Polysubstance 2.466 0.088 0.491 
       
  Cannabis x Infant Age x Birthweight 0.007 0.993 0.051 
  Cannabis x Infant Age x Polysubstance 3.618 0.029* 0.663 
  
Cannabis x Infant Age x Maternal 
Anxiety 2.157 0.119 0.438 
  
Cannabis x Birthweight x Maternal 
Anxiety 1.521 0.221 0.321 
  
Cannabis x Polysubstance x Maternal 
Anxiety 5.216 0.006* 0.826 
  Cannabis x Birthweight x Polysubstance 0.013 0.987 0.052 
       
  
Cannabis x Infant Age x Maternal 
Anxiety x Polysubstance 3.511 0.032* 0.649 
  
Cannabis x Infant Age x Maternal 
Anxiety x Birthweight 0.973 0.38 0.217 
  
Cannabis x Infant Age x Polysubstance 
x Birthweight 2.29 0.104 0.461 
  
Cannabis x Maternal Anxiety x 



















Table 4. Interaction between cannabis and other variables of interest on cortisol 
concentrations 
 
Cortisol Interaction Terms F p-val power 
  Cannabis x Maternal Anxiety 2.347 0.1 0.468 
  Cannabis x Infant Age 4.587 0.012* 0.769 
  Cannabis x Birthweight 5.405 0.006* 0.838 
  Cannabis x Polysubstance 0.104 0.901 0.066 
       
  Cannabis x Infant Age x Birthweight 0.348 0.707 0.105 
  Cannabis x Infant Age x Polysubstance 0.702 0.498 0.167 
  
Cannabis x Infant Age x Maternal 
Anxiety 0.511 0.601 0.133 
  
Cannabis x Birthweight x Maternal 
Anxiety 0.22 0.803 0.084 
  
Cannabis x Polysubstance x Maternal 
Anxiety 0.961 0.385 0.214 
  Cannabis x Birthweight x Polysubstance 0.449 0.639 0.122 
       
  
Cannabis x Infant Age x Maternal 
Anxiety x Polysubstance 2.425 0.092 0.482 
  
Cannabis x Infant Age x Maternal 
Anxiety x Birthweight 4.047 .020* 0.713 
  
Cannabis x Infant Age x Polysubstance 
x Birthweight 0.207 0.813 0.082 
  
Cannabis x Maternal Anxiety x 
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